Oramed Pharmaceuticals (ORMP) Enterprise Value (2010 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Enterprise Value came in at -$18.2 million in Q1 2026, up 77.04% YoY from -$10.3 million in Q1 2025, and up 64.63% on a QoQ basis from -$51.4 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Enterprise Value (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 17 years of Enterprise Value data on file, last reported at -$18.2 million in Q1 2026.
- Quarterly Enterprise Value rose 77.04% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.2 million (up 77.04% YoY) and the FY2025 annual result came in at -$51.4 million, up 38.94% from the prior year.
- Enterprise Value advanced to -$18.2 million in Q1 2026, from -$51.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$3.1 million in Q2 2025 to a low of -$155.0 million in Q3 2022.
- A 5-year average of -$89.6 million and a median of -$87.4 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 994.12% — and 2025, when it surged 96.42%.
- Tracing ORMP's Enterprise Value over 5 years: stood at -$152.6 million in 2022, then surged by 55.65% to -$67.7 million in 2023, then retreated by 24.27% to -$84.1 million in 2024, then surged by 38.94% to -$51.4 million in 2025, then soared by 64.63% to -$18.2 million in 2026.
- The last three Enterprise Value figures came in at -$18.2 million (Q1 2026), -$51.4 million (Q4 2025), and -$75.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 2.12 Bn |
| 10 | Oramed Pharmaceuticals | 199.66 Mn | 199.66 Mn | - | -50.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.69 Mn |
| Mar 31, 2026 | -18.17 Mn |
| Dec 31, 2025 | -51.36 Mn |
| Sep 30, 2025 | -75.33 Mn |
| Jun 30, 2025 | -3.13 Mn |
| Mar 31, 2025 | -79.13 Mn |
| Dec 31, 2024 | -84.13 Mn |
| Sep 30, 2024 | -100.48 Mn |
| Jun 30, 2024 | -87.44 Mn |
| Mar 31, 2024 | -99.78 Mn |
| Dec 31, 2023 | -67.70 Mn |
| Sep 30, 2023 | -126.53 Mn |
| Jun 30, 2023 | -7.99 Mn |
| Mar 31, 2023 | -152.29 Mn |
| Dec 31, 2022 | -152.63 Mn |
| Sep 30, 2022 | -154.98 Mn |
| Jun 30, 2022 | -127.95 Mn |
| Mar 31, 2022 | -134.46 Mn |
| Nov 30, 2021 | -38.92 Mn |
| Aug 31, 2021 | -87.55 Mn |